This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy, with letrozole, anastrozole or exemestane, lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hormone therapy plus ribociclib may work as well as chemotherapy followed by hormone therapy plus ribociclib for the treatment of high anatomic stage breast cancer with low recurrence risk.

Start Date14 Feb 2027

Sponsor / Collaborator

National Cancer Institute

JPRN-jRCTs031260249

/ Not yet recruitingPhase 2

A randomized study of Trastuzumab deruxtecan Against Second-line endocrine Therapy In hormone receptor-positive, HER2-low/ultralow metastatic breast cancer (TRANSITION)

Start Date29 Jun 2026

Sponsor / Collaborator-

ChiCTR2600126436

/ Not yet recruitingPhase 2

Neoadjuvant Trastuzumab and Pertuzumab Plus an Aromatase Inhibitor and Dalpiciclib in HR+/HER2+ Early Breast Cancer: A Single-Arm, Phase II Study

Start Date10 Jun 2026

Sponsor / Collaborator

Guangdong Hospital of Traditional Chinese Medicine

100 Clinical Results associated with Exemestane

100 Translational Medicine associated with Exemestane

100 Patents (Medical) associated with Exemestane

1,973

Literatures (Medical) associated with Exemestane

01 Sep 2026·COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY

Exemestane induces neurodevelopmental defects and behavioral diorder in zebrafish embryos by p53 signaling pathway

Article

Author: Wang, Ziang ; Yuan, Wenbin ; Shen, Qinyuan ; Xiao, Juhua ; Hu, Weitao ; Li, Weirong ; Hu, Yuhui ; Zhang, Shouhua ; Liao, Xinjun ; Xiao, Zhonghao ; Ge, Chenkai ; Li, Huimin ; Cao, Zigang

Exemestane, a third-generation oral aromatase inhibitor used clinically for breast cancer treatment, may exhibit potential developmental neurotoxicity, though the underlying mechanisms remain unclear. This study employed zebrafish embryos to investigate exemestane's impact on embryonic neurodevelopment. Embryos were exposed to exemestane (3, 6, and 9 μM) from 6 to 72 h post-fertilization (hpf). Exemestane exposure significantly increased larval mortality and malformation rates and reduced body length. It also impaired physiological functions, decreasing heart rate and spontaneous movement (tail coiling frequency). Critically, exemestane disrupted neurodevelopment, evidenced by reduced neural crest and neuronal cell populations, decreased spinal cord neuron width, and impaired larval motor capacity. Molecular analyses revealed elevated acetylcholinesterase, Ca²⁺-ATPase, and Na⁺/K⁺-ATPase activities, heightened oxidative stress, and increased apoptosis in the head region. Transcriptomics and qPCR further demonstrated downregulation of neurotransmitter-related genes and pathways involved in extracellular ligand-gated ion channel activity, nerve impulse propagation, and chemical synaptic transmission, alongside upregulation of the p53 signaling pathway. Importantly, p53 knockdown effectively rescued the observed neurodevelopmental defects and restored larval motility. Collectively, these findings demonstrate that exemestane induces embryonic developmental toxicity and neurodevelopmental defects in zebrafish, mediated in part through p53-dependent pathways. This study provides crucial preclinical evidence regarding exemestane's developmental neurotoxicity, offering insights for its clinical risk assessment and potential strategies to mitigate adverse effects.

01 Jun 2026·Obstetric Medicine

Delivery of a healthy infant in a woman with breast cancer inadvertently treated with exemestane and goserelin during pregnancy: A case report

Article

Author: Davis, Georgina ; Hicks, Amy ; Sit, Andrea

Exemestane and goserelin combination therapy is a well-established adjuvant treatment for hormone receptor-positive breast cancer. Both medications are contraindicated during pregnancy as their safety in the pregnant population is not yet established. We report a rare case of a 40-year-old multigravida with T1N0M0 breast cancer, receiving exemestane and goserelin post bilateral mastectomy. Despite over four years of amenorrhoea on goserelin, she conceived unexpectedly, and inadvertently continued both medications until she discovered she was pregnant at 13 weeks' gestation. The pregnancy was uncomplicated. A healthy female infant was delivered via caesarean section at 40 weeks. The notable features of this case are inadvertent pregnancy despite induction of amenorrhoea, and no evidence of congenital fetal anomaly despite exposure to exemestane and goserelin until 13 weeks' gestation. Women of child-bearing age receiving adjuvant endocrine therapy for breast cancer should be counselled to use effective contraception to minimise risk of harmful effects in pregnancy.

01 Jun 2026·Drug Testing and Analysis

Screening of Anabolic Androgenic Steroids in Illicit Dietary Supplements and Counterfeit Drugs Using LC–MS/MS and LC–QTOF/MS

Article

Author: Yoo, Geum Joo ; Kim, Hyun‐Kyung ; Kim, Aeseul ; Seo, Sowoon ; Kim, Hyunsuk ; Kim, Hyung Soo

ABSTRACT:

The manufacture and distribution of illicit drugs in the Republic of Korea are an increasing problem. We aimed to develop a rapid and reliable simultaneous analytical method for monitoring the illegal presence of anabolic androgenic steroids (AAS) in foods and drugs. Forty‐five AAS compounds were analyzed using a validated liquid chromatography–tandem mass spectrometry (LC–MS/MS) method in accordance with international standards. Liquid chromatography–quadrupole time‐of‐flight mass spectrometry (LC–QTOF/MS) has enabled the determination of representative fragment ion patterns. The validated method was applied to 95 real samples, including 11 foods, 40 dietary supplements, and 44 counterfeit drugs. The overall detection rate was 38.9%, with the highest rate observed in counterfeit drugs (81.8%), followed by dietary supplements (2.5%), whereas no AAS were detected in foods. When classified by formulation, injectables showed the highest detection rate (100.0%), followed by liquids (78.6%), tablets (58.3%), powders (20.0%), and capsules (3.3%). Frequently detected compounds included testosterone‐17‐propionate (0.001–119, 850.0 μg/g), testosterone‐17‐isocaproate (0.002–1442.7 μg/g), and nandrolone decanoate (0.01–120,023.0 μg/g). Anastrozole and exemestane, which are not currently included as LC–MS/MS target compounds, were also identified through LC–QTOF/MS. Furthermore, LC–QTOF/MS results revealed the presence of nonsteroidal compounds, including phosphodiesterase‐5 inhibitors and weight‐loss compounds, indicating potential health risks associated with the combined pharmacological effects of these substances. The analytical method developed in this study can be effectively used for both screening and quantification and offers practical applicability to regulatory monitoring and enhancement of public health protection.

News (Medical) associated with Exemestane

29 Jun 2026

·www.biospace.com

Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003

Publication Highlights Novel Intravenous Everolimus Formulation and Demonstrates Broad Potential of Deciparticle ™ Technology for Hydrophobic Therapeutics SAN DIEGO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB: OTLC) and Sapu Nano today announced today announced the publication of a peer-reviewed scientific manuscript validating its proprietary Deciparticle ™ nanoparticle platform through the successful development of Sapu003 , the Company's investigational intravenous everolimus formulation currently being evaluated in an ongoing Phase 1b clinical trial. The publication, "Intravenous Everolimus Formulation (Sapu003) for Clinical Trials," has been published in the International Journal of Molecular Sciences and provides the first comprehensive description of the Deciparticle ™ platform, including formulation design, scalable cGMP manufacturing, product characterization, stability, and preclinical evaluation. Publication Citation Min SH, Forero K, Putnam W, Anderson J, Hoff R, Lopp J, Trieu V, Ho K, Lee C. Intravenous Everolimus Formulation (Sapu003) for Clinical Trials. International Journal of Molecular Sciences. 2026;27(13):5775. doi:10.3390/ijms27135775. Everolimus is a well-established inhibitor of the mammalian target of rapamycin (mTOR) approved for the treatment of multiple cancers. However, because of its poor aqueous solubility and limited oral bioavailability, clinical use has historically been restricted to oral administration. Sapu003 was developed using the Deciparticle ™ platform to enable intravenous delivery through a stable nanoparticle formulation. The publication reports several significant achievements, including: Development of a stable intravenous everolimus formulation with mean particle sizes below 20 nanometers. A robust, scalable cGMP manufacturing process capable of producing clinical-grade material with high batch-to-batch reproducibility. Favorable product stability following lyophilization and refrigerated storage. Successful formulation of multiple hydrophobic therapeutic compounds, demonstrating the broader applicability of the Deciparticle ™ platform beyond everolimus. Potent preclinical antitumor activity supporting continued clinical development of Sapu003. "The publication of this work represents an important milestone for Sapu Bioscience," said Vuong Trieu, Ph.D., CEO and Chairman of Oncotelic. "Independent peer review validates not only the scientific foundation supporting Sapu003, but also the broader Deciparticle ™ platform. We believe this technology has the potential to address one of the longstanding challenges in drug development—enabling intravenous delivery of poorly water-soluble therapeutic compounds through a scalable and reproducible manufacturing process." Unlike many formulation technologies developed for a single product, the published research demonstrates that the Deciparticle ™ platform is compatible with wide range of hydrophobic molecules, including rapalogs, macrocyclic compounds, immunosuppressants, and selected peptide therapeutics. The Company believes this broad formulation capability may support future pipeline expansion and collaborative development opportunities. Sapu003 is currently being evaluated in an ongoing Phase 1b open-label dose-escalation study in patients with advanced mTOR-sensitive solid tumors. The study is assessing the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of weekly intravenous Sapu003 administered in combination with exemestane. "The publication marks the successful translation of the Deciparticle ™ platform from laboratory research to clinical-stage manufacturing," added Dr. Trieu. "As our Phase 1b clinical study progresses, we look forward to further evaluating the potential of Sapu003 while continuing to expand the application of the Deciparticle ™ platform to additional therapeutic programs." About Sapu003 Sapu003 is an investigational intravenous formulation of everolimus developed using Sapu Bioscience's proprietary Deciparticle ™ nanoparticle platform. The program is designed to overcome the formulation limitations associated with oral everolimus while enabling predictable intravenous administration for the treatment of patients with advanced cancers. About Deciparticle ™ Deciparticle ™ is Sapu Bioscience's proprietary nanoparticle formulation platform designed to enable intravenous delivery of poorly water-soluble therapeutic compounds. The technology combines amphiphilic polymer design with scalable cGMP manufacturing to generate stable nanoparticle formulations suitable for clinical development. The platform has demonstrated compatibility across multiple classes of hydrophobic therapeutic agents and is being evaluated for broader pharmaceutical applications. About Sapu Nano Sapu Nano (US) LLC is a clinical-stage biotechnology company developing the proprietary Deciparticle ™ nanomedicine platform for intravenous delivery of poorly water-soluble therapeutics. The Company's lead product candidate, Sapu003 (intravenous everolimus), is currently in Phase 1b clinical development for advanced mTOR-sensitive solid tumors. In addition to Sapu003, the Deciparticle ™ platform is being developed to enable next-generation nanomedicine products across oncology and other serious diseases. For more information, please visit . About Oncotelic Therapeutics Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company's mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. Beyond its internal programs, the Company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu's leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic's strategic position in oncology and rare disease therapeutics. Oncotelic also develops PDAOAI, its proprietary artificial intelligence platform for drug discovery, cleanroom automation, and AI-assisted GMP manufacturing. Through Oncotelic's relationship with SAPU Bio — an OEB-5 sterile injectable cGMP manufacturing facility — PDAOAI underpins the Company's joint development work with TechForce Robotics on intelligent automation for high-containment GMP biomanufacturing. For more information, please visit . Oncotelic Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this release other than statements of historical fact are forward-looking and are based on current expectations, estimates, and projections about our business and future plans. In some cases, you can identify forward-looking statements by terms such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "project," "forecast," "potential," "continue," and similar expressions (including the negative of such terms). Forward-looking statements in this release include, without limitation: the completion, scope, timing, capabilities, and commercialization of Phase 2 objectives under our joint manufacturing automation initiative with TechForce Robotics; the operational utility, performance, and customer adoption of the AI-Powered GMP Manufacturing Services Platform; the application of PDAOAI to sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring, and autonomous materials movement; the potential for future software licensing, automation deployment, manufacturing partnerships, and technology-enabled contract development and manufacturing services; the size, growth, and addressability of the pharmaceutical manufacturing software and automation market; the demonstration of PDAOAI and the integrated robotics platform at BIO International Convention 2026; the role of SAPU Bio as commercial deployment site and proving ground; regulatory interactions and potential approvals; development or commercialization of any product candidates within the Oncotelic / GMP Bio / Sapu ecosystem; future financings, strategic transactions, and/or public offerings involving our joint ventures or affiliates; and other statements that are not historical facts. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to: the competitive market of AI-enabled GMP manufacturing software and AI-enabled robotics; the performance and continued cooperation of our robotics and automation partners, including TechForce Robotics; the inherent uncertainties of drug discovery and development; our ability to enroll patients and complete studies on expected timelines; whether preclinical or early clinical findings (including biomarker associations) will be replicated in larger, controlled trials; regulatory developments in the United States and other jurisdictions; competitive developments; our ability to obtain or maintain intellectual property protection; our liquidity and access to capital; the performance of collaborators, suppliers, and manufacturers; and other risks described in our filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" section of our most recent Form 10-K and subsequent periodic reports. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise such statements, whether as a result of new information, future events, or otherwise, except as required by law. Investor & Media Contact Oncotelic Therapeutics, Inc. Investor Relations ir@oncotelic.com Corporate Communications IBN | Austin, Texas Editor@InvestorBrandNetwork.com 512.354.7000

Phase 1ImmunotherapyDrug Approval

24 Jun 2026

·www.fda.gov

FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer

On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.Full prescribing information for Ibrance will be posted on Drugs@FDA.Efficacy and SafetyEfficacy was evaluated in PATINA (NCT02947685), a randomized, open-label trial in 518 patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer who had no evidence of disease progression after induction treatment with a taxane and trastuzumab, with or without pertuzumab, for their advanced disease. Patients were randomized (1:1) to receive either palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy (fulvestrant or an aromatase inhibitor [anastrozole, letrozole, or exemestane]) or trastuzumab, with or without pertuzumab, and endocrine therapy alone. Patients received treatment until disease progression or unacceptable toxicity.The major efficacy outcome measure was investigator-assessed progression-free survival (PFS) per RECIST version 1.1. Overall survival (OS) was an additional efficacy outcome measure. A statistically significant improvement in investigator-assessed PFS was observed for palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy compared to trastuzumab, with or without pertuzumab, and endocrine therapy alone (Hazard ratio 0.76 [95% CI: 0.59, 0.97], 1-sided p-value 0.0134). Median PFS could not be adequately described because of censoring. At the time of the PFS analysis, OS data were not mature.The palbociclib prescribing information includes warnings and precautions for neutropenia, interstitial lung disease/pneumonitis, and embryo-fetal toxicity.Recommended DosageThe recommended palbociclib dosage is 125 mg orally once daily for 21 consecutive days, followed by seven days off treatment to comprise a complete cycle of 28 days. Refer to the prescribing information for the recommended dosages for trastuzumab, pertuzumab, and endocrine therapy.This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.Palbociclib received breakthrough therapy designation. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088.For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.Follow the Oncology Center of Excellence on X (formerly Twitter) @FDAOncology.

Clinical ResultDrug ApprovalPriority ReviewBreakthrough Therapy

25 Mar 2026

·allsci.com

Pfizer’s CDK4 atirmociclib cuts progression risk by 40% in second-line metastatic breast cancer trial

Pfizer (NYSE: PFE) reported Phase II results for atirmociclib in HR-positive, HER2-negative metastatic breast cancer, with the FOURLIGHT-1 trial meeting its primary endpoint by demonstrating a 40% reduction in the risk of disease progression or death compared to standard-of-care options. The data mark the first randomized Phase II readout for a selective CDK4 inhibitor in patients whose disease has progressed on prior CDK4/6 inhibitor therapy, a population with limited treatment options and no established targeted retreatment strategy. Trial specifics FOURLIGHT-1 is an open-label, randomized, multicenter Phase II study that enrolled 264 patients across 14 countries with HR-positive, HER2-negative advanced or metastatic breast cancer who had progressed after CDK4/6 inhibitor-based treatment. Patients were randomized to atirmociclib plus fulvestrant versus physician’s choice of fulvestrant alone or everolimus plus exemestane. The primary endpoint was investigator-assessed progression-free survival. Atirmociclib plus fulvestrant reduced the risk of progression or death by 40% versus control, with a hazard ratio of 0.60 (95% CI: 0.440–0.825; p=0.0007). The benefit was consistent across prespecified subgroups, including patients with visceral disease, those with prior CDK4/6 inhibitor treatment lasting less than or more than 12 months, and regardless of which CDK4/6 inhibitor was previously received. More than 90% of enrolled patients initiated atirmociclib within three months of their last CDK4/6 inhibitor treatment, indicating a population with recent disease progression rather than a prolonged treatment-free interval. Overall survival data were not mature, with approximately 20% of participants having had an event at the time of analysis. The safety profile was consistent with prior studies of atirmociclib. Discontinuation due to treatment-emergent adverse events occurred in 6.4% of patients on the atirmociclib arm, and no new safety signals were identified, according to the company. Detailed safety data were not disclosed and are expected at a future medical meeting. Development context Atirmociclib is an oral, selective inhibitor of cyclin-dependent kinase 4 (CDK4), a protein that drives the transition from G1 to S phase of the cell cycle. Unlike currently approved CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib, which inhibit both CDK4 and CDK6, atirmociclib targets CDK4 alone. The rationale for selective CDK4 inhibition centers on the hypothesis that sparing CDK6 may reduce hematologic toxicity, particularly neutropenia, which is the dose-limiting side effect of dual CDK4/6 inhibitors. Whether CDK4 selectivity translates into a clinically distinct efficacy or tolerability profile remains to be established in larger trials. The post-CDK4/6 inhibitor treatment landscape in HR-positive, HER2-negative metastatic breast cancer lacks a consensus targeted retreatment approach. Current options after progression on a CDK4/6 inhibitor include fulvestrant monotherapy, everolimus combined with exemestane, and more recently, agents such as elacestrant, an oral selective estrogen receptor degrader approved by the US FDA in 2023 for patients with ESR1-mutated tumors. The PI3K inhibitor alpelisib combined with fulvestrant is approved for PIK3CA-mutated disease. Capivasertib, an AKT inhibitor, received US FDA approval in 2023 in combination with fulvestrant for patients with PIK3CA/AKT1/PTEN-altered tumors. None of these therapies directly address the question of whether continued cell cycle inhibition through a next-generation mechanism can extend disease control after CDK4/6 inhibitor failure. Pfizer stated that a Phase III registrational study for atirmociclib in the first-line metastatic setting is ongoing, and results from a Phase II neoadjuvant study in early breast cancer will be presented at a future medical meeting. The company did not disclose a timeline for regulatory filing based on the FOURLIGHT-1 data or whether the Phase II results alone would support an accelerated approval pathway. The broader competitive context for next-generation CDK4 inhibitors includes programs from other companies, though atirmociclib is the first to report randomized Phase II data in the post-CDK4/6 inhibitor setting. Pfizer’s decision to advance atirmociclib into first-line and early-stage disease reflects a strategy to position the molecule as a potential replacement for, rather than a successor to, existing CDK4/6 inhibitors across treatment lines. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 2Clinical ResultDrug ApprovalPhase 3Accelerated Approval

100 Deals associated with Exemestane

External Link

KEGG	Wiki	ATC	Drug Bank
D00963	Exemestane	L02BG06	DB00990

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Estrogen receptor positive breast cancer	United States	Pfizer Inc.	21 Oct 1999
Breast Cancer	Switzerland	Pfizer Inc.	14 Oct 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	NDA/BLA	China	Cipla Ltd.	13 May 2022
Neoplasms	NDA/BLA	China	Benova(Tianjin)Innovation Pharmaceutical Research Co., Ltd.	13 May 2022
Premenopausal breast cancer	Phase 3	China	Pfizer Inc.	09 Aug 2018
Hormone receptor positive HER2 negative breast cancer	Phase 3	Austria	Pfizer Inc.	13 Mar 2014
Hormone receptor positive HER2 negative breast cancer	Phase 3	Austria	AstraZeneca PLC	13 Mar 2014
Hormone receptor positive HER2 negative breast cancer	Phase 3	Hungary	Pfizer Inc.	13 Mar 2014
Hormone receptor positive HER2 negative breast cancer	Phase 3	Hungary	AstraZeneca PLC	13 Mar 2014
Hormone receptor positive HER2 negative breast cancer	Phase 3	Israel	AstraZeneca PLC	13 Mar 2014
Hormone receptor positive HER2 negative breast cancer	Phase 3	Israel	Pfizer Inc.	13 Mar 2014
Hormone receptor positive HER2 negative breast cancer	Phase 3	Spain	AstraZeneca PLC	13 Mar 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO_SRC2026	Not Applicable	Perivascular epithelioid cell tumour	3	sirolimus + exemestane + gemcitabine	jwogyoszby(hgdoeaecmf) = rimhnngjey wuizgsqqpo (cpspevlxjm ) View more	Positive	09 Mar 2026
NCT04272801 (POWER, CTgov)	Phase 2	Early Stage Breast Carcinoma	84	Patient reported outcomes+letrozole+tamoxifen+exemestane+anastrozole	shvhuvdnaj = rvcuwowoec uxtgatogbm (gjvprigmac, zrykrbumzz - rfgvsbqmza) View more	-	22 Oct 2025
NCT00253422 (SoFEA, CTgov)	Phase 3	Breast Cancer	698	fulvestrant+anastrozole (Faslodex + Placebo)	xqfflycuph(oswleecpbn) = xcjtzuqadh lleeorozwj (bxcepcvkab, qeahtydxwg - nwqunmndao) View more	-	04 Jun 2025
				fulvestrant+anastrozole (Faslodex + Arimidex)	xqfflycuph(oswleecpbn) = vimtnbupwk lleeorozwj (bxcepcvkab, thsvdvuvfc - ajqffvyrvc) View more
NCT03300557 (CTgov)	Phase 2	Endometrioid intraepithelial neoplasia \| Endometrial Endometrioid Adenocarcinoma \| Endometrial Hyperplasia ... View more	40	Pharmacokinetic Study+Exemestane	qvxgepmdwm(igeaiymdsg) = wibtxvoivl ewyjnhznmk (hwsutgqvth, 0.22) View more	-	03 Jun 2025
SOFT and TEXT (ASCO2025)	Not Applicable	Hormone receptor positive breast cancer Adjuvant hormone receptor-positive	-	Exemestane + Ovarian Function Suppression	miwrvgbpzj(oohsfirbbp) = omxualikoi novubxautd (gfrdzrrune ) View more	Positive	30 May 2025
				Tamoxifen + Ovarian Function Suppression	miwrvgbpzj(oohsfirbbp) = vxnbgtrixt novubxautd (gfrdzrrune ) View more
NCT02990845 (Pubmed) Manual	Phase 1/2	ER-positive/HER2-negative Breast Cancer ER Positive \| HER2 Negative	15	Pembrolizumab + exemestane + leuprolide	qcgryanzmo(owtpmcqfqz) = twrjsoxvhz fkpwpmvrlv (tadivtogua ) View more	Positive	18 Dec 2024
NCT02028507 (PEARL \| GEICAM/2013-02 PEARL \| PEARL study, CTgov)	Phase 3	Metastatic breast cancer \| Hormone receptor positive HER2 negative breast cancer	693	palbociclib+Exemestane (Cohort 1: Palbociclib Plus Exemestane)	qxhvdoyprh(upgxofpjoe) = moenuyoppl nhyazeluqu (arqqtuilzm, sausmznrzc - rhhhhmphvj) View more	-	25 Sep 2024
				fulvestrant+palbociclib (Cohort 2: Palbociclib Plus Fulvestrant)	qxhvdoyprh(upgxofpjoe) = vxamkvlscm nhyazeluqu (arqqtuilzm, dtteyegtdm - aoufnmbjjq) View more
NCT06009627 (ESMO2024) Manual	Phase 2	Premenopausal breast cancer Neoadjuvant HER2 Negative \| HR Positive	32	Dalpiciclib, Exemestane, and Goserelin	qtcmgulaka(nlzustdnwg) = xzetfogdmw jjpynpzhgu (zsdjsixovf )	Positive	16 Sep 2024
				TAC (docetaxel, doxorubicin, and cyclophosphamide)	qtcmgulaka(nlzustdnwg) = mrhsxcotvk jjpynpzhgu (zsdjsixovf )
NCT03312738 (BOLERO-5, Pubmed) Manual	Phase 2	ER-positive/HER2-negative Breast Cancer HER2 Negative \| ER Positive	159	Everolimus (EVE) + Exemestane (EXE)	fvdnczfvyu(knwglrlsdl) = mklbugtyre lzihkyqxkz (aehurwweyc, 5.5 - 9.0)	Positive	21 Jun 2024
				Placebo (PBO) + Exemestane (EXE)	fvdnczfvyu(knwglrlsdl) = jqsxqpkfan lzihkyqxkz (aehurwweyc, 1.9 - 3.6)
NCT01594216 (CTgov)	Phase 2	Estrogen receptor positive breast cancer	25	Ruxolitinib+Exemestane (First Stage)	eujzdqnycw = susegjxjxi ypdiieurtt (jilafyffdl, dwiozaanxa - hghluaarpf) View more	-	12 Jun 2024
				Ruxolitinib+Exemestane (Second Stage)	eujzdqnycw = cizjaurxnc ypdiieurtt (jilafyffdl, unzyopdsaf - qhvvmwecpa) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis